Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Central Nervous System Neoplasms 1

Interventions

Radiotherapy 38Temozolomide 27Vincristine 15Chemotherapy, Adjuvant 11Carboplatin 11Filgrastim 10Granulocyte Colony-Stimulating Factor 9Etoposide 9Cyclophosphamide 9Lomustine 8Carmustine 7Cisplatin 6Peripheral Blood Stem Cell Transplantation 5etoposide phosphate 4Thiotepa 4Radiotherapy, Intensity-Modulated 4Radiotherapy, Conformal 4Procarbazine 4Neoadjuvant Therapy 4Irinotecan 4Immunohistochemistry 4Gene Expression Profiling 4Topotecan 3Radiosurgery 3Radiation 3lonafarnib 2Psychiatric Rehabilitation 2Microarray Analysis 2Methotrexate 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Central Nervous System Neoplasms × prexasertib × Clear all
NCT02808650 2023-12-20

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
30 enrolled 16 charts
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡